研究单位:[1]Peking University People's Hospital[2]Peking University Institute of Hematology, Peking University People's Hospital,Peking University People's Hospital[3]Beijing Hospital[4]Beijing Friendship Hospital[5]Navy General Hospital, Beijing[6]Beijing Tongren Hospital[7]Peking University Insititute of Hematology,Beijing 1816670,China
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.